Introduction {#sec1}
============

Glial cell line-derived neurotrophic factor (GDNF) protects and promotes the survival and function of midbrain dopaminergic neurons in cell culture[@bib1] and in animal models of Parkinson's disease (PD).[@bib2] Intracranial ectopic delivery of GDNF has been tested in clinical trials for PD. Most of the studies conducted on PD patients reported an increased putamenal ^18^Fluoro-dopamine uptake, suggesting a neurotrophic effect.[@bib3], [@bib4], [@bib5], [@bib6], [@bib7], [@bib8] However, of major concern is the lack of clinical benefit upon GDNF delivery into the brain.[@bib3], [@bib4], [@bib5], [@bib6], [@bib7], [@bib8], [@bib9], [@bib10], [@bib11] Results from the most recent double-blind, placebo-controlled phase II trial showed no significant improvements in PD patients where GDNF was delivered into the putamina once per month for 40 weeks compared with the placebo group.[@bib3] Notably, however, a *post hoc* analysis revealed that 9 (43%) patients who were treated with GDNF, but no placebo patients, demonstrated a significant motor improvement in the OFF state,[@bib3] providing hope for late-onset efficacy. The same patients who participated in the study also took part in a second open-label phase of the trial where all received monthly infusions of GDNF for another 40 weeks.[@bib4] Results showed significant improvements in both groups, again suggesting that GDNF may offer hopes for PD patients, although any conclusions derived from the second part of the trial must take into account that the trial was not placebo controlled.[@bib4] At the time of this writing, a trial of adeno-associated virus, serotype 2 (AAV2) vector delivering GDNF in the putamina of subjects with advanced PD is ongoing. However, although results from the phase I study reported no side effects, AAV2-GDNF delivery also had no effect on the progression of PD evaluated until 18 months post-infusion.[@bib5]

Contrary to the clinical trials, in PD preclinical models, ectopically delivered GDNF is effective.[@bib2]^,^[@bib12], [@bib13], [@bib14], [@bib15] However, efficacy comes with side effects. Nigrostriatal delivery of ectopic GDNF results in a decrease in striatal and nigral levels of tyrosine hydroxylase (TH), the rate-limiting enzyme of catecholamine biosynthesis;[@bib16], [@bib17], [@bib18] aberrant arborization of striatal dopaminergic fibers toward the GDNF injection site due to non-physiological chemoattraction;[@bib18], [@bib19], [@bib20] hyperactivity;[@bib19]^,^[@bib21], [@bib22], [@bib23] loss of body weight;[@bib24] and only a transient elevation in dopamine turnover for a few months upon viral delivery.[@bib16]^,^[@bib19]^,^[@bib23] All of these, alone or in combination, may emerge once efficacy in humans is achieved, and they are likely to present a clinical concern. Therefore, it is important to first establish a safe mode of action in animal models. This objective formed the first rationale of our study.

The second rationale of our study relates to the safety concern related to the development of GDNF mimetic that activates GDNF receptor RET (REarranged during Transfection).[@bib25] Activating mutations in RET result in early cancer syndrome named multiple endocrine neoplasia type 2 (MEN2) with tumors in thyroid, adrenal glands, and tongue,[@bib26]^,^[@bib27] and GDNF overexpression in testes results in testicular cancer in mice.[@bib28] Systemic application of GDNF mimetic to treat PD for years may therefore result in cancer. This concern has substantially reduced enthusiasm in developing GDNF mimetic. Our second objective was to analyze the long-term outcome of elevated endogenous GDNF expression on tumor formation.

Previously, we generated a mouse model where a constitutive, about 2-fold elevation in endogenous GDNF levels was achieved by replacing the 3′ untranslated region (3′ UTR) of *Gdnf* with a 3′ UTR that is less responsive to inhibitory molecules such as microRNAs (GDNF hypermorphic mice, *Gdnf*^wt/hyper^).[@bib29] Because the 3′ UTR-mediated regulation occurs at the post-transcriptional level, increase of endogenous GDNF levels in *Gdnf*^wt/hyper^ mice is limited to the cells that naturally transcribe Gdnf. We found that young 10-week-old *Gdnf*^wt/hyper^ mice have improved motor coordination, enhanced dopamine system function, are protected in a chemically induced model of PD, and do not display adverse outcomes related to ectopic GDNF overexpression.[@bib29]^,^[@bib30] Very recently, others used long non-coding RNAs to enhance endogenous GDNF protein translation and reached a similar conclusion in young animals.[@bib31] In order to proceed with endogenous GDNF-based drug development and GDNF mimetic research, a preclinical safety evaluation of long-term elevation of endogenous GDNF is important. Chronic elevation in endogenous GDNF may trigger side effects similar to ectopic GDNF during a longer time period, trigger new side effects such as neuropsychiatric conditions that relate to chronically elevated striatal dopamine,[@bib32], [@bib33], [@bib34], [@bib35] or result in cancer. Here we report the results of analysis of five cohorts of aged *Gdnf*^wt/hyper^ mice and wild-type gender-matched littermate controls for the dopamine system, multiple behavioral endpoints covering dopamine-related brain functions, and cancer formation.

Results {#sec2}
=======

This study was designed to investigate the outcome of a long-term, about 2-fold increase in endogenous GDNF levels by analyzing aged *Gdnf*^wt/hyper^ mice and wild-type littermate controls. We used a set of behavioral tests to evaluate motor function and other endpoints that associate with changes in GDNF levels and the brain dopamine system. At the endpoint of about 19 months of age, mice were analyzed for various brain dopamine system parameters and for tumor formation. An overview of the side effects and physiological functions that associate with the dopamine system and with GDNF/RET signaling analyzed in this study is depicted in [Figure 1](#fig1){ref-type="fig"}.Figure 1An Overview of Side Effects and Physiological Functions That Associate with the Dopamine System Function and/or with GDNF/RET Signaling Analyzed in This Study

Analysis of Motor Function and Learning in Aged *Gdnf*^wt/hyper^ Mice {#sec2.1}
---------------------------------------------------------------------

Behavioral analysis of *Gdnf*^wt/hyper^ mice using gender-matched littermates as controls was initiated at 15--17 months of age and concluded by 17--19 months of age. Quantitative PCR (qPCR) analysis revealed a similar about 2-fold increase in *Gdnf* mRNA levels in old *Gdnf*^wt/hyper^ mice, as reported previously in young *Gdnf*^wt/hyper^ animals ([Figure 2](#fig2){ref-type="fig"}A).[@bib29] Ectopic GDNF overexpression in the nigrostriatal tract has been reported to cause a loss in body weight,[@bib24] which may influence outcome of motor tests. We observed no difference in body weight between *Gdnf*^wt/wt^ and *Gdnf*^wt/hyper^ mice ([Figure 2](#fig2){ref-type="fig"}B). First, old *Gdnf*^wt/wt^ and *Gdnf*^wt/hyper^ mice were analyzed with a variety of tests that evaluate motor coordination and learning under forced movement conditions. We performed an accelerating rotarod test, on 2 consecutive days, with three trials per day. The performance of *Gdnf*^wt/hyper^ mice improved significantly on day 2 ([Figure 2](#fig2){ref-type="fig"}C). Notably, on day 2, aged *Gdnf*^wt/hyper^ animals performed as well as untrained (day 1) young wild-type mice at 10 weeks of age in a comparable genetic background ([Figure 2](#fig2){ref-type="fig"}C, dotted line).[@bib30] Next, we performed the vertical grid test, which evaluates motor function and the righting-reflex. Time to turn upward, to climb to the upper edge, and to fall off the grid were measured with one trial per day for 2 consecutive days. We found that *Gdnf*^wt/hyper^ animals turn faster on day 1 and have a faster learning curve compared with controls at day 2 ([Figure 2](#fig2){ref-type="fig"}D). This is consistent with the observed increase in motor learning in the rotarod experiment. In addition, *Gdnf*^wt/hyper^ mice reached the upper edge of the grid faster ([Figure 2](#fig2){ref-type="fig"}E), and none of the *Gdnf*^wt/hyper^ mice fell off the grid during the experiment ([Figure 2](#fig2){ref-type="fig"}F). Thus, constitutively increased endogenous GDNF levels do not cause changes in body weight but improve motor learning and the righting-reflex in 15- to 17-month-old mice.Figure 2Increased Endogenous GDNF Level Improves Motor Learning in Old *Gdnf*^wt/hyper^ Mice(A) Levels of *Gdnf* mRNA in the dorsal striatum (dSTR), substantia nigra (SN), and prefrontal cortex (PFC) of *Gdnf*^wt/wt^ and *Gdnf*^wt/hyper^ mice quantified by quantitative PCR and normalized to *Actb* expression level. Welch's t test: p = 0.0039 (dSTR), p = 0.0015 (SN), and p = 0.0060 (PFC). (B) Animal body weight before (START) and after (END) experiments. Welch's t test: p = 0.561 (START) and p = 0.666 (END). (C) Latency to fall in accelerating rotarod test. ANOVA comparing 15- to 17-month-old *Gdnf*^wt/wt^ and *Gdnf*^wt/hyper^ animals (black and red lines, respectively) revealed significant genotype effect (day 1: p = 0.295, day 2: p = 0.009). ANOVA comparing the performance between days 1 and 2 within the same group showed significant improvement in *Gdnf*^wt/hyper^ animals (p = 0.017), but not in wild-type littermates (p = 0.081). The gray dotted line represents the rotarod performance of *Gdnf*^wt/hyper^ mice tested in Mätlik et al.[@bib30] at 10 weeks of age. (D) Latency to turn in the vertical grid test at days 1 and 2 of the experiment. Welch's t test comparing *Gdnf*^wt/wt^ and *Gdnf*^wt/hyper^ mice at day 1 (p = 0.041) and day 2 (p = 0.01). Paired Student's t test comparing the latency to turn of *Gdnf*^wt/wt^ (p = 0.758) and *Gdnf*^wt/hyper^ mice (p = 0.049) at day 1 versus day 2. (E) Latency to reach the top of the grid in the vertical grid test. Welch's t test: p = 0.037. (F) Latency to fall off the grid in the vertical grid test. Welch's t test: p \< 0.001. (A) dSTR and SN: n = 6 *Gdnf*^wt/wt^ and n = 7 *Gdnf*^wt/hyper^; PFC: n = 7 *Gdnf*^wt/wt^ and n = 5 *Gdnf*^wt/hyper^. (B--F) n = 25 *Gdnf*^wt/wt^ and n = 20 *Gdnf*^wt/hyper^. Data are presented as mean ± SEM. ∗p \< 0.05, ∗∗p \< 0.01, ∗∗∗p \< 0.001. RR, rotarod; VG, vertical grid.

Analysis of Voluntary Motor Behavior and Muscle Strength in Aged *Gdnf*^wt/hyper^ Mice {#sec2.2}
--------------------------------------------------------------------------------------

Next, we performed tests to investigate voluntary motor behavior of *Gdnf*^wt/wt^ and *Gdnf*^wt/hyper^ mice. First, we performed the beam walking test. No differences were recorded between *Gdnf*^wt/wt^ and *Gdnf*^wt/hyper^ mice ([Figures 3](#fig3){ref-type="fig"}A and 3B). We then investigated motor coordination and balance in the multiple static rods (MSRs) test, which consists of a series of five wooden rods of decreasing diameters. The latencies to turn to face the fixed end of the rod and then to travel to the supporting beam were recorded, and no differences were detected between genotypes ([Figures 3](#fig3){ref-type="fig"}C and 3D). Because muscle strength may influence the outcome of motor tests, we measured this parameter. In the coat hanger test, we observed no difference between genotypes in the coat hanger score, latency to reach the lines, and latency to fall ([Figures 3](#fig3){ref-type="fig"}E--3G; see [Materials and Methods](#sec4){ref-type="sec"} for details). Similar results were obtained in the forelimb grip strength test ([Figure 3](#fig3){ref-type="fig"}H). Our data suggest that motor balance under voluntary movement conditions and muscle strength in aged *Gdnf*^wt/hyper^ mice are comparable with their wild-type littermates.Figure 3Voluntary Motor Behavior and Muscular Strength Are Not Affected in Aged *Gdnf*^wt/hyper^ Mice(A) Number of crossed lines during beam walking test. Welch's t test: p = 0.319. (B) Latency to fall from the beam in the beam walking test. Mann-Whitney U test: p = 0.721. (C) Latency to turn on each rod in the multiple static rods test. Multiple t test: rod 1 (p = 0.428), rod 2 (p = 0.652), rod 3 (p = 0.859), rod 4 (p = 0.833), and rod 5 (p = 0.304). (D) Time to reach the platform (escape and travel to the supporting beam) on each rod in the multiple static rods test. Multiple t test: rod 1 (p = 0.517), rod 2 (p = 0.26), rod 3 (p = 0.374), rod 4 (p = 0.526), and rod 5 (p = 0.404). (E) Score given in the coat hanger test. Welch's t test: p = 0.652. (F) Latency to reach the lines in the coat hanger test. Welch's t test: line 1 (end of horizontal part), p = 0.458; line 2 (diagonal part of the coat hanger), p = 0.823. (G) Latency to fall off in the coat hanger test. Mann-Whitney U test: p = 0.375. (H) Maximal forepaw pulling force measured in the grip strength test. Welch's t test: p = 0.06. (A, B, and E--H) n = 25 *Gdnf*^wt/wt^ and n = 20 *Gdnf*^wt/hyper^. (C and D) n = 18 *Gdnf*^wt/wt^ and n = 13 *Gdnf*^wt/hyper^. Data are presented as mean ± SEM. BW, beam walking; CH, coat hanger; MSR, multiple static rod.

Analysis of the Dopamine System and Related Functions in Aged *Gdnf*^wt/hyper^ Mice {#sec2.3}
-----------------------------------------------------------------------------------

We measured total tissue dopamine levels in the striatum of *Gdnf*^wt/wt^ and *Gdnf*^wt/hyper^ animals using high-performance liquid chromatography (HPLC). We detected increased striatal dopamine levels in *Gdnf*^wt/hyper^ mice ([Figure 4](#fig4){ref-type="fig"}A), whereas the levels of the main dopamine metabolites, 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA), were unaltered ([Figures 4](#fig4){ref-type="fig"}B and 4C). Next, we counted the number of dopamine cells in the substantia nigra (SN) pars compacta (SNpc) and analyzed dopaminergic fibers in the dorsal striatum (dSTR) by TH immunostaining in *Gdnf*^wt/wt^ and *Gdnf*^wt/hyper^ mice ([Figure 4](#fig4){ref-type="fig"}F). We found a small but significant increase in the number of dopamine neurons in the SNpc of *Gdnf*^wt/hyper^ animals ([Figure 4](#fig4){ref-type="fig"}D). The intensity and pattern of TH immunostaining in the dSTR did not significantly differ between the genotypes ([Figure 4](#fig4){ref-type="fig"}E). *Th* mRNA levels in the dSTR and SN did not differ between *Gdnf*^wt/wt^ and *Gdnf*^wt/hyper^ mice ([Figure 4](#fig4){ref-type="fig"}G). Our results indicate that about a 2-fold lifelong increase of endogenous GDNF increases striatal dopamine levels and the number of dopamine neurons in the SNpc without affecting the level of *Th* mRNA in the dSTR and SN, and without causing aberrant sprouting of TH-positive fibers.Figure 4Sustained Increase in GDNF and Dopamine Cell Numbers and Striatal Levels in Old *Gdnf*^wt/hyper^ Mice Does Not Cause Adverse Effects(A--C) HPLC analysis of striatal (A) dopamine and its metabolites (B) DOPAC and (C) HVA. Welch's t test: p = 0.016 (dopamine), p = 0.249 (DOPAC), and p = 0.359 (HVA). (D) TH-positive cell counts indicating the number of dopaminergic neurons in the SNpc of *Gdnf*^wt/wt^ and *Gdnf*^wt/hyper^ mice. Welch's t test: p = 0.03. (E) Striatal optical density measurement of TH-positive fibers in *Gdnf*^wt/wt^ and *Gdnf*^wt/hyper^ mice. Welch's t test: p = 0.095. (F) Representative coronal brain slices showing TH-immunoreactive cell bodies in the SNpc (upper panel, low and higher magnification) and TH-immunoreactive fibers in the striatum (lower panel, low and higher magnification of the dSTR) of *Gdnf*^wt/wt^ and *Gdnf*^wt/hyper^ mice. (G) Levels of *Th* mRNA in the dSTR and SN of *Gdnf*^wt/wt^ and *Gdnf*^wt/hyper^ mice quantified by quantitative PCR and normalized to the geometric mean of *Actb*, *Gapdh*, and *Pgk1* expression levels. Welch's t test: p = 0.646 (dSTR) and p = 0.898 (SNpc). (H) Total distance traveled in the open field test calculated in 5-min blocks. Multiple t test: 5 min (p = 0.546), 10 min (p = 0.300), 15 min (p = 0.635), 20 min (p = 0.593), 25 min (p = 0.261), and 30 min (p = 0.491). (I) Time spent in the center of the open field arena during the open field test calculated in 5-min blocks. Multiple t tests: 5 min (p = 0.632), 10 min (p = 0.767), 15 min (p = 0.834), 20 min (p = 0.846), 25 min (p = 0.875), and 30 min (p = 0.626). (J) Response to startle stimulus with different prepulse stimuli, relative to response to startle stimulus alone. Two-way repeated-measures ANOVA test, genotype effect p = 0.792. (K and L) Percentage of time spent in quadrants of the water maze during the probe (K) trial 1 and (L) trial 2. Welch's t test, genotype effect probe 1: NE p = 0.268, SE p = 0.564, SW p = 0.356, NW p = 0.633; probe 2: NE p = 0.763, SE p = 0.925, SW p = 0.56, NW p = 0.635. "(T)" indicates the quadrant that contained the escape platform during training. (A--C) n = 7 *Gdnf*^wt/wt^ and n = 6 *Gdnf*^wt/hyper^. (D) n = 6 *Gdnf*^wt/wt^ and n = 5 *Gdnf*^wt/hyper^. (E) n = 5 *Gdnf*^wt/wt^ and n = 4 *Gdnf*^wt/hyper^. (G) dSTR: n = 6 *Gdnf*^wt/wt^ and n = 6 *Gdnf*^wt/hyper^; SN: n = 7 *Gdnf*^wt/wt^ and n = 7 *Gdnf*^wt/hyper^. (H--L) n = 25 *Gdnf*^wt/wt^ and n = 20 *Gdnf*^wt/hyper^. Data are presented as mean ± SEM. ∗p \< 0.05, ∗∗p \< 0.01. NE, northeast; NW, northwest; SE, southeast; SW southwest.

Nigrostriatal recombinant GDNF injection results in hyperlocomotion[@bib19]^,^[@bib21], [@bib22], [@bib23] and genetic modifications, or drugs that increase dopamine and dopamine transmission cause hyperactivity[@bib36], [@bib37], [@bib38], [@bib39] and induce anxiety.[@bib34]^,^[@bib35] We did not observe differences in the distance traveled or time spent in the center of the arena in open field tests, suggesting a lack of hyperlocomotion and anxiety-like behaviors in *Gdnf*^wt/hyper^ animals, respectively ([Figures 4](#fig4){ref-type="fig"}H and 4I). Enhanced striatal dopamine function is associated with schizophrenia.[@bib32]^,^[@bib33] We measured sensorimotor gating using the prepulse inhibition (PPI) test, a parameter altered in schizophrenic patients and mice with a schizophrenia-like phenotype,[@bib40]^,^[@bib41] and found no difference between genotypes ([Figure 4](#fig4){ref-type="fig"}J). Ectopic overexpression of GDNF in the hippocampus of aged rats improves cognitive function,[@bib42] and reduced levels of endogenous GDNF in *Gdnf* knockout (KO) heterozygous mice affect learning performance in the Morris water maze (MWM) test.[@bib43] Analysis of animals using the MWM test revealed no difference in spatial learning and memory between genotypes ([Figures 4](#fig4){ref-type="fig"}K and 4L). Thus, despite the sustained increase in striatal dopamine levels, an about 2-fold constitutive elevation of endogenous GDNF does not result in enhanced spontaneous locomotion or anxiety, impaired sensorimotor gating, or alteration in spatial learning or memory in aged *Gdnf*^wt/hyper^ mice.

Analysis of Cancer in Aged *Gdnf*^wt/hyper^ Mice {#sec2.4}
------------------------------------------------

Overexpression of GDNF in the testes causes seminomatous germ cell tumors in 100% of mice by 12 months of age.[@bib28] Mutations resulting in constitutive activation of GDNF receptor RET convert the *RET* gene into an oncogene.[@bib44] The resulting condition, MEN2B, triggers tumors in endocrine organs, most prominently in the thyroid (C-cell hyperplasia) and adrenal glands (chromaffin cells hyperplasia), as well as in the tongue.[@bib27] In a mouse model genocopying the MEN2B Met918Thr mutation, tumors appear between 2--5 and 8--12 months of age in MEN2B homozygous and heterozygous mice, respectively.[@bib26] Anatomical and histopathological evaluation of the adrenal glands, thyroid, tongue, and testes of 17- to 19-month-old *Gdnf*^wt/wt^ and *Gdnf*^wt/hyper^ mice revealed no cancer, neoplasia, or abnormal cell masses ([Figures 5](#fig5){ref-type="fig"}A and 5B). Anatomical evaluation of other organs, including liver, spleen, kidneys, and eyes, detected no tumors ([Figure 5](#fig5){ref-type="fig"}B). The observed histological alterations were sporadic and characteristic of old age ([Figure 5](#fig5){ref-type="fig"}B).Figure 5*Gdnf*^wt/hyper^ Mice Do Not Develop Multiple Endocrine Neoplasia or Testicular Tumors(A) Representative 4-μm-thick slices from adrenal glands, thyroid, tongue, and testes. All slides were stained with hematoxylin and eosin. Scale bars are indicated in each image. (B) Main findings from anatomical and histopathological evaluation of different organs in 17- to 19-month-old *Gdnf*^wt/wt^ and *Gdnf*^wt/hyper^ mice.

Discussion {#sec3}
==========

Previously we reported that about a 2-fold elevation of endogenous GDNF levels increases motor coordination and brain dopamine function without side effects in young mice.[@bib29]^,^[@bib30] This conclusion was recently confirmed by others,[@bib31] suggesting that means to elevate endogenous GDNF expression may constitute a safe and efficient treatment route for PD. One possible way to stimulate GDNF signaling is GDNF mimetic, i.e., small-molecule GDNF receptor RET agonists that penetrate the blood-brain barrier (BBB) and can be delivered systemically. However, constitutively activating mutations in RET result in MEN,[@bib26]^,^[@bib27] posing a serious safety concern for potential future chronic application of GDNF mimetic. Before making a substantial investment into developing GDNF mimetic, it would therefore be important to analyze the long-term outcome of a chronic increase in endogenous GDNF. If, similar to mutations in RET with consequent constitutive activation of RET signaling, a chronic increase in GDNF results in MEN, investment into GDNF mimetic would hardly be rational. Likewise, another critical organ are the testes, where ectopic GDNF overexpression results in cancer in mice.[@bib28] Very recently, hematopoietic stem cell transplantation-based macrophage-mediated GDNF delivery was shown to be effective and safe in a mouse model of PD.[@bib45] Chen et al.[@bib45] reported that about 5 months after GDNF delivery, no tumors were found, although a need for long-term evaluation with a focus on MEN2 organs was noted by the authors.[@bib45] Increased endogenous GDNF may also result in new side effects that manifest only upon chronic increase in endogenous GDNF expression upon aging. We hypothesized that upon aging some adverse effects reported for ectopic GDNF will possibly appear in *Gdnf*^wt/hyper^ mice, and that we will likely detect new side effects or MEN2-like neoplastic changes or cancer. To our surprise, we found no adverse effects. Instead, aged *Gdnf*^wt/hyper^ mice showed increased motor learning and performance in accelerating rotarod and vertical grid tests. After 1 day of training, the performance level of aged *Gdnf*^wt/hyper^ mice was comparable with that of young 10-week-old wild-type mice. How a constitutive increase in endogenous GDNF expression increases motor learning and function until high age remains currently unknown, but is an interesting subject of future inquiry. Endogenous GDNF is expressed in several central nervous system (CNS) regions and cell types that regulate motor function, including striatum,[@bib29]^,^[@bib46] motor cortex, cerebellum, and spinal cord.[@bib47], [@bib48], [@bib49], [@bib50] Future investigation, including generation and analysis of conditional GDNF hypermorphic mice, may reveal in which of the above-mentioned CNS regions and how an elevation of endogenous GDNF is responsible for increased motor learning and function in aged animals.

We also found that aged *Gdnf*^wt/hyper^ mice display sustained elevation in striatal tissue dopamine levels and a sustained increase in the number of dopamine cells in the SNpc with no evidence for *Th* mRNA downregulation or aberrant sprouting of TH-positive dopamine fibers in the striatum. We noticed variability in *Th* mRNA expression levels, especially in the SN. However, analysis of striatal dopamine level and number of TH-positive cells in the SN followed by measurement of striatal TH-positive fibers suggest that TH protein function and level remain in the physiological range despite the observed alterations at the mRNA level. A small but non-significant trend for an increase in TH-positive fibers in *Gdnf*^wt/hyper^ animals likely reflects a small but significant increase in dopamine cell numbers in the SN. We also found no decrease in body mass or hyperlocomotion in *Gdnf*^wt/hyper^ mice. Because dopamine neurons are the main RET-expressing neurons in the CNS, and dopamine neurons in mice lacking RET do not respond to GDNF *in vitro* and *in vivo*,[@bib51]^,^[@bib52] we hypothesize that GDNF mediates those effects via RET receptor as opposed to two other reported receptors for GDNF in the CNS: neural cell adhesion molecule (NCAM) and Syndecan-3.[@bib53]^,^[@bib54] Unfortunately, quantitative analysis of RET phosphorylation *in vivo* in the brain is very challenging, and many laboratories, including ours, have failed to generate reproducible results, leaving quantitation of RET activation in *Gdnf*^wt/hyper^ animals a future challenge.

The effects of long-term ectopic and endogenous GDNF elevation are summarized in [Table 1](#tbl1){ref-type="table"}. Our previous[@bib29]^,^[@bib30] and current results suggest that constitutive about 2-fold elevation of endogenous GDNF is safe and enhances dopamine system function, improves motor performance, and may overcome the adverse effects associated with ectopic overexpression. Our results encourage future studies on increased endogenous GDNF using various means,[@bib29], [@bib30], [@bib31]^,^[@bib55] support further development of recently created GDNF mimetic,[@bib25]^,^[@bib56] and encourage other means of moderate GDNF application including macrophage-mediated GDNF delivery.[@bib45]Table 1Main Outcomes of Elevated Endogenous GDNF in Aged *Gdnf*^wt/hyper^ MicePhenotypes Reported in Previous StudiesMethodReferenceLong-Term Elevation of Endogenous GDNF (This Study)Increase in dopamine turnover, but no changes in striatal dopamine tissue levelstriatal or nigral recombinant lentiviral vector delivery of GDNF in unlesioned animals[@bib16]elevated and sustained striatal dopamine levelsDownregulation of TH levels in the STR and SNstriatal recombinant lentiviral vector delivery of GDNF[@bib16], [@bib17], [@bib18]no changes in TH levels in the STR and SNStriatal dopaminergic fibers sprouting toward GDNF injection sitenigrostriatal recombinant GDNF injection and viral gene delivery[@bib18], [@bib19], [@bib20]no increase of striatal TH-positive dopaminergic fibers densityHyperactivitynigrostriatal recombinant GDNF injection[@bib19]^,^[@bib21], [@bib22], [@bib23]no difference in spontaneous locomotor activityLoss in body weightnigrostriatal virus-mediated GDNF delivery[@bib24]no change in body weightTumors in testes in all mice used by 12 months of agetransgenic overexpression of GDNF in undifferentiated spermatogonia[@bib28]no tumors found in testesThyroid and adrenal neoplasiaGDNF receptor RET constitutive activation due to point mutation (MEN2B mice)[@bib26]no tumors found in thyroid and adrenal glands

Materials and Methods {#sec4}
=====================

Animals {#sec4.1}
-------

Mice were 15--17 months old when the behavioral experiments started and 17--19 months old by the end of the experiments. Because the oestrus cycle is believed to enhance experimental variation and because of the considerable costs of aging studies, we analyzed only male mice. However, in our previous study,[@bib30] we observed improved motor coordination in young *Gdnf*^wt/hyper^ male mice and a trend for improved motor coordination in young female mice.[@bib30] In the future it would be of great interest to analyze female mice for the same parameters. Wild-type littermates were used as controls in all experiments. Animals were maintained in 129Ola/ICR/C57bl6 mixed genetic background and maintained at temperature-controlled conditions at 20°C--22°C under a 12-h/12-h light/dark cycle at relative humidity of 50%--60%. Cages and bedding material (aspen chips; Tapvei Oy, Finland) were changed every week, and wooden tube and aspen shavings were provided as enrichment. Mice received food and water *ad libitum*. Altogether, five cohorts of mice were used in this study for a total of 80 animals (41 *Gdnf*^wt/wt^ and 39 *Gdnf*^wt/hyper^ mice). The experiments performed in each cohort are as follows: cohort 1 (7 *Gdnf*^wt/wt^ + 7 *Gdnf*^wt/hyper^), all of the behavioral tests listed below (except MSRs), HPLC, TH immunohistochemistry, and stereological analysis of TH-positive cells in the SNpc; cohort 2 (6 *Gdnf* ^wt/wt^ + 4 *Gdnf* ^wt/hyper^), all of the behavioral tests listed below and the striatal optical density (OD) measurement of TH-positive fibers; cohort 3 (12 *Gdnf*^wt/wt^ + 9 *Gdnf*^wt/hyper^), all of the behavioral tests listed below and gene expression analyses via qPCR (7 *Gdnf*^wt/wt^ + 7 *Gdnf*^wt/hyper^); cohort 4 (12 *Gdnf*^wt/wt^ + 12 *Gdnf*^wt/hyper^), post mortem anatomical and histopathological evaluation of the testes; and cohort 5 (4 *Gdnf*^wt/wt^ + 7 *Gdnf*^wt/hyper^), post mortem anatomical analysis of liver, spleen, kidneys, and eyes and histopathologic evaluation of adrenal glands, thyroid, tongue, and testes.

All experiments were conducted following the 3R principles of the European Union (EU) directive 2010/63/EU governing the care and use of experimental animals, and were approved by the County Administrative Board of Southern Finland (license numbers ESAVI-2010-09011/Ym-23 and ESAVI/11198/04.10.07/2014). The protocols were authorized by the national Animal Experiment Board of Finland.

Behavioral Tests {#sec4.2}
----------------

Behavioral tests, including rotarod, vertical grid, beam walking, coat hanger, grip strength, open field, and PPI, were performed as described previously by Mätlik et al.[@bib30]

MSRs {#sec4.3}
----

The MSRs test was performed to investigate motor coordination and balance. The MSRs are a series of five 60-cm-long wooden rods of decreasing diameters (rod 1: 27 mm; rod 2: 21 mm; rod 3: 15 mm; rod 4: 11 mm; and rod 5: 8 mm), each perpendicularly screwed at one end to a supporting beam. The apparatus was elevated 60 cm above a soft surface. The animal was placed 2 cm from the distal end of the rod, facing away from the supporting beam. The latencies to turn to face the fixed end of the rod and then to travel to the supporting beam were recorded in a period of a maximum of 3 min.

MWM {#sec4.4}
---

The MWM was used to evaluate spatial learning and memory. The system consisted of a black circular swimming pool (Ø 120 cm) and an escape platform (Ø 10 cm) submerged 0.5 cm under the water surface in the center of one of four imaginary quadrants. The animals were released to swim in random positions facing the wall, and the time to reach the escape platform (maximum time 60 s) and the swimming distance were measured in every trial. In addition, thigmotaxis, the time spent swimming within the outermost ring of the pool (10 cm from the wall), was measured. Two training blocks consisting of three trials each were conducted daily. The interval between trials was 4--5 min and between training blocks about 5 h. The hidden platform remained in a constant location for 3 days (six initial training sessions) and was thereafter moved to the opposite quadrant for 2 days (four reverse training sessions). Probe trials were conducted approximately 18 h after the last initial and reverse training sessions. Mice were allowed to swim in the maze for 60 s without the platform available. Spatial memory in the probe trials was estimated by preference of swimming in the trained region (imaginary circular area of Ø 30 cm, around the previous platform location) over swimming in corresponding regions in the three other quadrants. After the second probe trial, the mice were tested for one block of three trials, with the platform made visible in the quadrant not employed previously.

Tissue Isolation {#sec4.5}
----------------

After deep anesthesia with CO~2~, mice were euthanized by cervical dislocation followed by decapitation. The brain was quickly removed from the skull, immersed in ice-cold saline, and placed in an ice-cooled brain block (Stoelting, Wood Dale, IL, USA). Brain regions of interest were collected as described by Kumar et al.[@bib29] using a puncher (inner diameter, 2 mm), snap frozen, and stored at −80°C until processed.

RNA Isolation and qPCR {#sec4.6}
----------------------

Total RNA was isolated from frozen tissues using Trizol Reagent (Thermo Fisher Scientific) according to the manufacturer's protocol, and RNA quantity and quality (absorbance 260/280 nm \> 1.8) were assessed using a NanoDrop (NanoDrop Technologies, Wilmington, DE, USA). A total of 200 ng DNase I (Thermo Fisher Scientific, MA, USA)-treated total RNA was reverse transcribed to complementary DNA using random hexamer primers and RevertAid Reverse Transcriptase (Thermo Fisher Scientific, MA, USA). Complementary DNA was diluted 1:10 and stored at −20°C until analysis. qPCR was performed with BioRad C1000 Touch Thermal Cycler upgraded to CFX384 System (Bio-Rad), supplied with SYBR Green I Master (Roche) and 250 pmol primers, in 10 μL total volume in 384-well plates. The following primer pairs were used: *Gdnf* (forward \[F\]: 5′-CGCTGACCAGTGACTCCAATATGC-3′, reverse \[R\]: 5′-TGCCGCTTGTTTATCTGGTGACC-3′), *Th* (F: 5′-CCCAAGGGCTTCAGAAGAG-3′, R: 5′-GGGCATCCTCGATGAGACT-3′), *Actb* (F: 5′-CTGTCGAGTCGCGTCCA-3′, R: 5′-ACGATGGAGGGGAATACAGC-3′), *Gapdh* (F: 5′-CCTCGTCCCGTAGACAAAA-3′, R: 5′-ATGAAGGGGTCGTTGATGGC-3′), and *Pgk1* (F: 5′-TTGGACAAGCTGGACGTGAA-3′, R: 5′-AACGGACTTGGCTCCATTGT-3′). Each sample was run in triplicate. Expression level of *Gdnf* was normalized to *Actb* housekeeping gene expression level, and expression level of *Th* was normalized to *Actb* and to the geometric mean of *Actb*, *Gapdh*, and *Pgk1* housekeeping genes expression level. Both reference systems for *Th* revealed a similar result, and data using the geometric mean of *Actb*, *Gapdh*, and *Pgk1* as a reference are presented in [Figure 4](#fig4){ref-type="fig"}G. Results for a biological repeat were discarded when the C~q~ value for one or more of the replicates was 40 or 0, or when the C~q~ difference between replicates was \>1.

HPLC {#sec4.7}
----

Monoamines and their respective metabolites were analyzed from the dissected brain samples as described previously[@bib57] using HPLC with electrochemical detection. The values are presented as nanograms per gram of wet tissue weight.

TH Immunohistochemistry {#sec4.8}
-----------------------

For striatal OD measurement of TH-positive fibers (cohort 2), mice were anesthetized with sodium pentobarbital (100 mg/kg intraperitoneally \[i.p.\]) and intracardially perfused with PBS followed by 4% paraformaldehyde (PFA) in 0.1 M phosphate buffer (pH 7.4). The brains were then fixed in 4% PFA overnight and stored in phosphate buffer containing 20% sucrose at 4°C. For striatal dopamine level measurement and TH immunohistochemistry (cohort 1), an alternative "light" perfusion method was used. In brief, the brains were cooled after PBS perfusion, and dSTR was dissected from the rostral part of the brain for HPLC analysis, whereas the posterior part containing the midbrain was fixed overnight in 4% PFA for stereological analysis of TH-positive cells in the SNpc. Coronal striatal (30 μm) and nigral (40 μm) serial sections were cut using a freezing microtome and stored at −20°C until processed for TH immunostaining. Staining of freely floating brain sections was performed using standard immunohistochemical procedures, and the following antibodies were used: rabbit anti-TH (1:2,000; AB 152; Millipore) and biotinylated goat anti-rabbit (1:200; BA1000; Vector Laboratories). Vectastain Elite ABC peroxidase kit (Vector Laboratories) was used for visualization. Further details are provided by Mijatovic et al.[@bib58]

Stereological Analysis of TH-Positive Cells {#sec4.9}
-------------------------------------------

The number of TH-positive neurons in the SNpc was assessed by a person blinded to the identity of the samples, as described by Kumar et al.[@bib29] In brief, cells positive for TH were counted at the medial region of the SNpc, around the medial terminal nucleus. From each animal, every third section between −3.08 and −3.28 mm caudally from bregma was selected (three sections per animal). StereoInvestigator (MBF Bioscience) was used to outline the SNpc, and positively stained cells were counted within the defined outlines according to the optical dissector rules. Cells were counted at regular predetermined intervals (x = 100 μm; y = 80 μm) within the counting frame (60 μm × 60 μm) superimposed on the image using a 60 × oil objective (Olympus BX51 \[Olympus Optical\] equipped with an Optronics camera). The counting frame positions within the SNpc were randomized by the software. The coefficient of error (CE) was calculated as an estimate of precision, and values \<0.1 were accepted. Failure in staining or perfusion resulting in spoiled sections was an exclusion criterion.

Striatal OD Measurement {#sec4.10}
-----------------------

A person who was blinded to the identity of the genotypes performed the OD analysis of the striata of *Gdnf*^wt/wt^ and *Gdnf*^wt/hyper^ mice. Images were generated using 3DHISTECH Pannoramic 250 FLASH II digital slide scanner at Genome Biology Unit supported by HiLIFE and the Faculty of Medicine, University of Helsinki and Biocenter Finland. Measurements of striatal TH-positive fibers were performed using Fiji Is Just ImageJ (ImageJ, Version 1.52).[@bib59] Image calibration was done by using a calibrated OD step tablet containing 21 steps with a density range of 0.05--3.05 OD. Analysis was done from five to six striatal sections from each animal, and the final reading was calculated as an average. Dorsal and ventral striatum were analyzed separately, and the nonspecific background correction in each section was done by subtracting the OD value of the corpus callosum from the striatal OD value of the same section. Failure in staining or perfusion resulting in spoiled sections was an exclusion criterion.

Histopathology {#sec4.11}
--------------

Mice were autopsied at 17--19 months of age. Anatomical evaluation of mice upon autopsy and histopathological assessment of tissues associated with GDNF/RET signaling-induced cancer (thyroid, adrenal glands, tongue, and testes) and four control organs selected at random for detailed examination (liver, spleen, eyes, and kidneys) were performed by a professional pathologist at the Finnish Centre for Laboratory Animal Pathology (FCLAP), Faculty of Veterinary Medicine, University of Helsinki. The tissue samples were fixed in phosphate-buffered 4% PFA or 4% formaldehyde and routinely processed into histological slides: dehydrated, embedded in paraffin, and sectioned at 4 μm thickness. All slides were stained with hematoxylin and eosin. Microscopic findings were classified with standard pathological nomenclature, and severities of findings were graded as minimal, mild, moderate, marked, or severe. Grades of severity for microscopic findings are subjective. No tumors were found in the samples examined.

Statistical Analysis {#sec4.12}
--------------------

Comparisons between two groups were analyzed with a Welch's t test or Mann-Whitney U test. Comparisons between the same subjects were performed with a paired Student's t test. Analysis of rotarod test and PPI test was performed with a two-way analysis of variance (ANOVA). Assessments with p \< 0.05 were considered significant.
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